Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
CONCLUSIONS: Ipilimumab could be considered after anti-PD-1 treatment. Treatment with ipilimumab following anti-PD-1 therapy showed beneficial effects in patients with normal levels of LDH, 2 or less number of metastatic locations, and BRAF-mutated melanoma. However, further studies are required to confirm our results as the study included a low number of patients with BRAF mutation-positive melanoma. No significant increase in toxicity was detected with the use of ipilimumab after anti-PD-1 therapy.
PMID: 32554313 [PubMed - as supplied by publisher]
Source: Advances in Medical Sciences - Category: Biomedical Science Authors: Cybulska-Stopa B, Rogala P, Czarnecka AM, Ługowska I, Teterycz P, Galus Ł, Rajczykowski M, Dawidowska A, Piejko K, Suwiński R, Mackiewicz J, Rutkowski P Tags: Adv Med Sci Source Type: research
More News: Biomedical Science | Immunotherapy | Melanoma | Skin Cancer | Study | Toxicology | Yervoy